Gut Bacterium’s Secreted Compounds Shielded Mice From Radiation Damage

If you or someone you love is facing radiotherapy for cancer, the gut is usually the last thing on anyone's mind, until the diarrhea, nausea, and cramping start. A new study offers an early but intriguing clue about why some intestines cope better with radiation than others, and it traces back to a single, common gut microbe. Researchers found that a compound made by that bacterium, not the bacterium itself, protected the intestinal lining of irradiated mice by calming a cellular stress response that radiation triggers.

Key takeaways

• Mice that survived a lethal radiation dose had unusually high pre-existing levels of the gut bacterium Limosilactobacillus reuteri (L. reuteri, a common probiotic species), and giving other mice its secreted components before irradiation protected their intestines.
• The protection worked by lowering radiation-induced oxidative stress (cell damage caused by unstable molecules called reactive oxygen species, or ROS) in intestinal epithelial cells, the cells lining the gut.
• This is mouse and cell-line research only; no human trial has tested this, and the exact protective molecule within the bacterial secretions has not been identified.
• The approach could eventually matter for cancer patients undergoing abdominal or pelvic radiotherapy, but it is not a proven or available intervention.

L. reuteri secretions curbed radiation-induced oxidative stress

Researchers at Pusan National University in South Korea, publishing in Probiotics and Antimicrobial Proteins, found that secreted components from the gut bacterium Limosilactobacillus reuteri (LR-SCs, short for LR-secreted components) protected mice and intestinal cells from radiation damage by reducing reactive oxygen species (ROS), unstable molecules that radiation generates and that damage DNA and cell structures when they build up faster than the body can clear them. Mice given LR-SCs for 7 days before a lethal radiation dose survived at significantly higher rates and lost less body weight than untreated mice, and their intestinal cells showed markedly less oxidative stress and less cell death than those of unprotected animals.

The team first noticed the connection by comparing mice that survived a lethal 7.5 Gray (Gy, a unit of absorbed radiation dose) exposure to those that did not. Survivors had harbored higher pre-exposure levels of three Lactobacillus-family species in their feces, including Lacticaseibacillus casei, Lactobacillus salivarius (LS), and L. reuteri (LR). When researchers pre-treated separate groups of mice with either live LS or live LR bacteria for 8 weeks, both improved survival against the same lethal dose. But when the researchers switched from live bacteria to just their secreted components, only L. reuteri's secretions protected the animals. Mice given LS-secreted components remained just as vulnerable to radiation as untreated controls.

Cancer patients undergoing radiotherapy could eventually benefit

Radiation therapy is used in more than half of all cancer treatment plans, and damage to the surrounding healthy gastrointestinal tissue is one of its most common and disruptive side effects. According to background cited in the study, roughly 90% of cancer patients who receive radiotherapy to the abdomen or pelvis develop acute gastrointestinal symptoms, including diarrhea, vomiting, and weight loss, within three months of treatment. That matters for anyone managing inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or a generally sensitive gut who is also facing cancer treatment, since radiation-induced intestinal injury can compound existing gut symptoms. The researchers frame secreted bacterial components, sometimes called postbiotics, as an appealing alternative to giving cancer patients live probiotic bacteria, since live probiotics carry some safety concerns in people with weakened immune systems, including a risk of bloodstream infection.

How the protective effect was tested and measured

The researchers used a combination of live-mouse experiments and lab-grown human intestinal cells (a small intestinal epithelial cell line called FHs 74 Int) to test the effect at multiple levels. In mice, they measured survival rates and body weight for 15 days after a 7.5 Gy whole-body dose, along with intestinal villus height (the finger-like projections that line the gut and absorb nutrients) and tissue damage under the microscope one day after irradiation. In cells, they directly measured ROS levels and mitochondrial mass, the cell's energy-producing structures, using fluorescent biosensors and flow cytometry after 5 or 10 Gy of X-ray exposure. RNA sequencing of ileum tissue (a section of the small intestine) further showed that mice given LR-SCs had 486 genes shift in expression that were not affected by LS-SCs, including a drop in two apoptosis-related genes, Cideb and Casp6, that flag cells for programmed cell death.

A proteomic analysis (a survey of the actual proteins present in the bacterial secretions) also found that L. reuteri's secretions shared 22 proteins with another radioprotective species, Lactobacillus acidophilus, that were absent from the non-protective L. salivarius secretions. Two of the shared proteins, 6-phosphogluconate dehydrogenase (6PGD) and thioredoxin reductase (TrxR), both belong to cellular systems that neutralize ROS, offering a plausible mechanical explanation for why L. reuteri's secretions, specifically, blunted radiation damage.

What this could mean, and what it does not mean yet

For now, this is not something a person facing radiotherapy can act on. The researchers did not test LR-SCs in humans, did not isolate the specific protective molecule from the mixture of proteins in the secretions, and used a single laboratory strain of L. reuteri, not a store-bought probiotic supplement. Nothing here validates any commercial probiotic product as protective against radiation side effects, and patients undergoing radiotherapy should not interpret this as a reason to start or stop any probiotic regimen without talking to their oncology team, since the authors themselves note that live probiotics can carry infection risks in people with cancer.

That said, the mechanism is a genuinely useful clue. If a defined bacterial secretion, rather than a living organism, can meaningfully reduce oxidative stress in irradiated intestinal cells, it points toward a category of postbiotic therapies that could sidestep the infection risk of live probiotics altogether. This is the kind of finding that is worth watching, and worth asking a treating oncologist about if and when it reaches clinical testing, rather than something to act on today.

Open questions the study leaves unanswered

The authors are explicit that several questions remain open. They do not know whether the radioprotective effect is a general property of L. reuteri as a species or specific to the particular strain used in this study. They also could not pin down which single molecule, or combination of molecules, within the secreted components is doing the protective work, since the secretions contain a heterogeneous mix of proteins and other compounds. The researchers additionally note that antibiotic pretreatment, used to clear out the mice's existing gut bacteria before the experiments, can itself disrupt the microbiome in ways that might have influenced results, and that deeper studies of the antioxidant signaling pathways involved, such as the NRF2 and KEAP1 systems that regulate the body's own antioxidant response, would strengthen the case.

What comes next for this research

The study authors describe LR-SCs as a "potential prophylactic agent" worth pursuing for reducing radiotherapy side effects, but they frame this explicitly as a direction for further research rather than a near-term treatment. Next steps they flag include identifying the exact active component within the secretions, testing whether the effect holds across different L. reuteri strains, and running the kind of mechanistic and eventually clinical studies needed before anything like this could be considered for cancer patients. No timeline for human testing has been established.

Common Questions

Is L. reuteri the same as probiotics sold in stores? L. reuteri is a real probiotic species found in some commercial supplements, but this study used secreted components from a specific laboratory strain grown under controlled conditions, not a consumer product, so the findings do not confirm any store-bought supplement offers this protection.

Could this help people already undergoing radiotherapy today? No. This research has only been tested in mice and lab-grown cells, and the study authors have not tested it in humans or identified the exact protective compound, so it is not an available or validated intervention.

Why did the researchers use bacterial secretions instead of live bacteria? Live probiotic bacteria can pose safety risks for cancer patients with weakened immune systems, including bloodstream infections, so the researchers wanted to test whether just the molecules the bacteria release could deliver the same protection without that risk.

What does oxidative stress have to do with radiation damage? Radiation generates reactive oxygen species, unstable molecules that damage DNA and cell structures faster than the body can neutralize them; reducing that oxidative burden was the specific mechanism through which the bacterial secretions protected intestinal cells in this study.

References

Hyeyun Kim, Se-Hui Lee, Sun Park, et al. (2026). Gut Limosilactobacillus reuteri-secreted Components Mitigate Susceptibility to Radiation by Alleviating Oxidative Stress in the Intestinal Epithelium. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-026-11189-2